EyeControl

Company Overview

Snapshot

Founded in January 2016 by Or Retzkin, Izhack Davidovich, and Itai Kornberg, EyeControl operates with 11–50 employees. The company has raised a total of $15.21M across 14 funding rounds from 14 investors. In April 2025, EyeControl secured equity crowdfunding from ExitValley.

Business overview

EyeControl is a medical technology company that develops an AI-powered eye-tracking platform to facilitate communication for mechanically ventilated patients. Its core technology enables effective communication, connects patients with families and caregivers, and provides healthcare teams with actionable insights. The company serves the healthcare industry, focusing on critical care and homecare settings, and operates within the Health Tech & Life Sciences sector, specifically in medical devices and digital healthcare.

Strategic signal

In June 2024, EyeControl was highlighted for its revolutionary medical technology, indicating continued innovation in the health tech sector. This signals to investors a strong commitment to advancing patient care through technology and a potential for further market penetration with its AI-powered communication solutions.

Company Intelligence Q&A

What is EyeControl's primary focus in product development?

In June 2022, EyeControl expanded its R&D program with EyeControl-Pro for delirium, indicating a focus on addressing cognitive and mental health outcomes in critical care.

Has EyeControl received any grants recently?

In May 2024, EyeControl received a grant from the Google AI Startup Fund. Additionally, in January 2024, the company received a grant from a2 collective.

What is the market availability of EyeControl's products?

In October 2018, the EyeControl headset became available on the NHS Supply Chain, expanding its reach to patients in the UK.

What is EyeControl's approach to reducing delirium in ICU patients?

In January 2024, news highlighted EyeControl's innovative headset as a method to potentially reduce delirium in ICU patients, showcasing the company's efforts to improve patient outcomes beyond communication.